Latest news with #Exondys51
Time of India
2 days ago
- Health
- Time of India
Oligonucleotides: The Tiny Molecules, Reshaping Modern Medicine
Diseases, not just treated but edited out. Oligonucleotide therapies are making it possible. Imagine if doctors could fix a disease by correcting the problem in your DNA, like editing a sentence in a book. That's not science fiction anymore. It's happening today with a new kind of treatment called oligonucleotide therapy. These treatments don't just treat symptoms like fever or pain. Instead, they go to the root cause of your genes and try to fix what's wrong. What Are Oligonucleotide therapies? Oligonucleotides (we'll call them short DNA or oligos) are tiny man-made pieces of genetic material, like DNA or RNA. They are manufactured in a laboratory and are used to send special messages inside the body's cells. These messages can help turn off harmful genes, repair damaged ones, or change how they work. Oligonucleotide therapies come in different types, like antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers. Each type works a bit differently, but they all aim to fix faulty genetic messages inside our cells. Depending on the type of oligo, they act in different ways: Block harmful proteins: Some oligos stick to bad RNA and stop it from making harmful proteins. Destroy faulty messages: Others call in the body's enzymes to break down the bad RNA before it can do damage. Fix genetic mistakes: Some oligos help the body 'edit' or 'splice' RNA properly, correcting how a gene message is read. In short, oligo therapies are smart medicines that repair the body's internal instructions. How Are They Helping People? In recent years, oligos have been used to treat some very serious illnesses, especially those caused by faulty genes. Some real-world U.S. FDA-approved examples include: Spinraza: Helps children with spinal muscular atrophy (SMA) walk and breathe better. Exondys 51: Used for Duchenne muscular dystrophy (DMD) to help muscles stay stronger for longer. Tofersen: Approved to treat a rare genetic form of ALS, a nerve disease. Olezarsen: A new drug that treats a rare condition where fat levels in the blood become dangerously high. Qfitlia: Approved to treat Hemophilia A or B, with or without inhibitors, the first and only such treatment of its kind. More are on the way. Over 30 oligo-based treatments are being tested in clinical trials for diseases like cancer, heart problems, blood disorders, and even rare brain conditions. Offer new hope for patients with serious genetic diseases. Why Oligonucleotides Are a Game-Changer in Drug Development? Here's why experts believe oligonucleotides are changing the future of medicine: Super-Targeted Treatment: These medicines work like a GPS. They find and fix specific genetic problems without affecting the rest of the body. This means more effective treatment and fewer side effects. Quick to Develop: Oligonucleotide drugs can be made faster than traditional medicines because they follow a simpler design. This helps scientists respond more quickly, especially during health emergencies or for rare diseases. Fewer Side Effects: Since they only act on the problem area, they're often safer and easier on the body. Many patients tolerate them well. Work Even in Small Doses: These medicines are powerful. Just a small amount can be enough to get the job done, reducing the need for heavy doses. Can Treat Many Illnesses: From rare genetic disorders and cancers to viral infections like hepatitis, oligonucleotide therapies can be used for a wide range of diseases. This makes them very versatile. Fixes Problems at the Gene Level: Unlike other drugs that just manage symptoms, oligonucleotides can turn off faulty genes, fix how genes are read, or stop harmful proteins from forming. Better Technology Means Better Results: With new ways to deliver these drugs into the body and protect them from breaking down, they are now more stable, more accurate, and more effective. Challenges Ahead: Despite their potential, oligonucleotide therapies face several significant hurdles: High development and manufacturing costs Complex regulatory approval processes Limited public and clinical awareness There is a need for specialized delivery systems to reach target tissues. Their large molecular size prevents easy entry into cells, requiring innovative delivery approaches such as inhalable aerosols or nano formulations. These methods are less invasive than monoclonal antibodies and may also reduce adverse effects like hypersensitivity reactions. Currently, over 30 second-generation antisense oligonucleotides (ASOs) are in clinical trials for neurological, cardiovascular, metabolic, and cancer-related conditions. However, challenges such as short half-life, rapid clearance, and inefficient cellular uptake persist. Advanced solutions, like lipid- or polymer-based nanoparticles and ligand-conjugated oligos, are actively being developed to overcome these barriers. While trials for chronic respiratory diseases remain limited, the FDA's approval of oligo-based drugs for disorders like spinal muscular atrophy and Duchenne muscular dystrophy marks a major step forward. Ongoing research into chemical modifications and synergistic combinations is focused on enhancing stability, reducing toxicity, and improving targeted delivery. These challenges also present strategic opportunities. With investments in biotech infrastructure, workforce training, and public–private partnerships, India is well-positioned to become a global leader in oligonucleotide therapeutics. Why India Should Pay Attention: While most approved oligo therapies have emerged from biotech giants in the US and Europe, India has significant potential to emerge as a hub for research, development, and manufacturing in this field. India already houses a growing ecosystem of biotech startups, academic research labs, and genetic testing companies. Our country's strength in cost-effective synthesis of oligonucleotides (used in diagnostics, sequencing, and therapeutics) positions us well for expansion into therapeutics. Imagine an India where advanced gene therapies are not just imported at high prices, but developed locally, affordably, and ethically. The Road Forward: The science of oligonucleotide therapies is still young but advancing rapidly. From rare genetic diseases to common cancers, the potential applications are vast. Global momentum is building, and India must not be left behind. By supporting genomics education, building strong research ecosystems, and encouraging regulatory innovation, we can move from being importers of advanced therapies to becoming innovators and exporters. Artificial Intelligence is further accelerating this progress. From AI-powered design of oligonucleotides to predictive models for delivery and efficacy, smart algorithms are helping scientists develop safer, more precise, and faster therapies. For millions of patients waiting for real cures, these tiny molecules carry huge hope. Bangalore-based Barcode Biosciences, a trusted manufacturer of high-quality oligonucleotides for biopharma, research, and diagnostics laboratories across India, the Middle East, and beyond, is planning to step into GMP-grade therapeutic oligo production in near future, empowering pharma and driving the next wave of transformative treatments. Author: Dr. Ramprasad Kuncham, Scientist, Managing Director & CEO of Barcode Biosciences, is driving India's genomic advancement through expertise in oligonucleotide synthesis, pioneering the launch of the nation's first end to end gene synthesis , and sequencing services "Get the latest news updates on Times of India, including reviews of the movie Coolie and War 2 ."
Miami Herald
18-07-2025
- Business
- Miami Herald
Major biotech stock tumbles 35 percent after major rare disease setback
Biotech stories typically tread a very fine line between promise and pressure. Sometimes a company that's been a pioneer in rare diseases suddenly finds itself at a crossroads. Don't miss the move: Subscribe to TheStreet's free daily newsletter With years of headline-making science behind it, one major biotech stock is now facing a moment that flips the script on how investors and regulators see its future. It's not about a singular decision, but a pattern coming into focus. What's surfacing now is a test of just how far early bets can stretch. Image source: Nagle/Bloomberg via Getty Images Sarepta Therapeutics (SRPT) has been at the core of the conversation around Duchenne muscular dystrophy (DMD) treatments, but it hasn't been without its controversies. Back in 2016, Sarepta won FDA approval for Exondys 51, the first drug to target a specific DMD mutation. It got the approval through the agency's accelerated pathway, which fast-tracks promising treatments to reach patients based on early data. However, that decision sparked debate. The clinical trial included just 12 boys, and while dystrophin, a key muscle protein, saw a boost, its skeptics questioned whether that translated into real-world benefits. Related: JPMorgan reveals 9 stocks with major problems Europe's regulators dismissed the drug in 2018, and U.S. insurers placed tight restrictions on coverage. Nevertheless, the therapy carved out a strong niche, serving a small group of patients with exon 51 mutations. Sarepta followed things up with Vyondys 53, another exon-skipping treatment, and saw a similar pattern emerge. It followed an initial pushback, eventual FDA approval, and ongoing requests for stronger data from insurers and clinicians. Even with these challenges, the DMD market remains strong. The disease affects close to 13,000 boys in the U.S., and treatments topped $2 billion in North American sales last year. Globally, that market could potentially reach $6.5 billion by 2034. More News: Moody's drops 2-word warning on housing marketRigetti shakes up quantum computing with bold advanceTikTok's next move has Google and Meta sweating bullets Sarepta's biggest bet came with Elevidys, a gene therapy priced at $3.2 million per dose. The treatment was estimated to help roughly 90% of U.S. DMD patients. That massive scale and price reignited debate around cost, access, and evidence. The company's path has been ambitious. However, with investor confidence shaken by safety questions and shifting strategy, the road ahead seems mostly rocky. Sarepta Therapeutics is feeling the heat after a third patient death linked to its gene therapy program came to light. Following the development, its stock tanked roughly 35% on July 18, having lost 88% year-to-date. The company confirmed that an early-stage trial patient being treated for limb-girdle muscular dystrophy died last month from acute liver failure. That news adds to the scrutiny over the safety of Sarepta's experimental treatments. This follows two earlier deaths tied to Elevidys, a gene therapy for DMD developed with Roche (RHHBY). Related: UnitedHealth's shocking move to please Wall Street Those patients were said to be in advanced stages of the disease and had lost their ability to walk. Sarepta says it acted quickly, notifying regulators and investigators "in an appropriate and timely manner." Nonetheless, the fallout is growing. The company has shut down a related clinical trial and paused the distribution of Elevidys for non-ambulatory patients. It's discussing safety protocols for high-risk groups with the FDA. Adding to the duress, Sarepta announced a massive corporate shake-up this week. It rolled out a sweeping restructuring plan, cutting 36% of its workforce (500 jobs). It's also looking to stop producing multiple drug programs to focus more tightly on siRNA and gene-silencing therapies, which potentially could be a lot more promising pipeline bets. Management expects these cost-cutting measures to save around $400 million annually starting in 2026. Given the combination of patient deaths, halted trials, and a shift away from some therapies, Sarepta may now be entering a major reset phase. Related: One Washington move could shake Big Pharma to its core The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
